D G Alleva Selected Research

NBI6024

1/2006

Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

D G Alleva Research Topics

Disease

3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2006 - 07/2000
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2006
1	Autoimmune Diseases (Autoimmune Disease) 08/2002
1	Multiple Sclerosis 08/2002

Drug/Important Bio-Agent (IBA)

3	Peptides (Polypeptides)IBA 10/2006 - 08/2002
2	Amino Acids FDA Link 10/2006 - 01/2001
2	EpitopesIBA 01/2006 - 01/2001
2	Insulin (Novolin)FDA Link 01/2006 - 01/2001
2	LigandsIBA 01/2006 - 08/2002
2	AntigensIBA 08/2002 - 01/2001
1	myelin oligodendrocyte glycoprotein (35-55)IBA 10/2006
1	CCR ReceptorsIBA 10/2006
1	NBI6024IBA 01/2006
1	Myelin Basic ProteinIBA 08/2002
1	CytokinesIBA 07/2000
1	Interleukin-10 (Interleukin 10)IBA 07/2000
1	Interleukin-12 (IL 12)IBA 07/2000
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2000

Therapy/Procedure

1	Immunomodulation 01/2006
1	Therapeutics 01/2001